• Spectrum Pharmaceuticals Inc., of Henderson, Nev., received about $25 million from the exercise of long-term warrants. The warrants had a strike price of $6.62. Proceeds will be used to bolster the company's reserves, now totaling nearly $160 million, as it commercializes oncology drugs Fusilev (levoleucovorin) and Zevalin (ibritumomab tiuxetan) and develops oncology drugs apaziquone and belinostat.